Maker Of Generic Prilosec Wins Patent Ruling

WASHINGTON (CN) – Mylan Inc.’s generic version of the heartburn medication Prilosec does not infringe on AstraZeneca’s patents, the Federal Circuit ruled.     The appellate court affirmed a judgment by U.S. District Judge Barbara Jones of New York, who found that the generic omeprazole – the active ingredient in Prilosec – did not infringe on AstraZeneca’s patents for “oral pharmaceutical preparations for omeprazole.”     AstraZeneca failed to prove that the generic drugs contain significant amounts of carbonates, the alkaline reacting compound in Prilosec.